{"product_id":"recombinant-human-il-2-protein-bhp22200024","title":"Recombinant Human IL-2 Protein","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}.bhp-desc .bhp-app-wrap{overflow-x:auto}.bhp-desc .bhp-app-table{width:100%;border-collapse:collapse;margin:12px 0 18px;font-size:14px}.bhp-desc .bhp-app-table th{background:#e8f0fb;color:#003366;text-align:left;padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-app-table td{padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eRecombinant Protein · Interleukin\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRecombinant Human IL-2 Protein\u003c\/strong\u003e is a full-length, glycosylated monomer expressed in \u003cstrong\u003ehuman cells\u003c\/strong\u003e. It is manufactured in an animal-free, xeno-free and tag-free format and supplied lyophilized without carrier protein, at \u0026gt;95% purity by SDS-PAGE and endotoxin \u0026lt;0.5 EU\/µg.\u003c\/p\u003e\n\u003cp\u003eIL-2 is used to support proliferation and survival of activated T cells, to expand NK cells for functional and cytotoxicity assays, to expand Vδ2+ and other γδ T-cell populations, and to study IL-2 receptor, STAT5 and survival signaling. Activity is confirmed by CTLL-2 cell proliferation, and two peer-reviewed studies identify this IL-2 or its catalog number.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eExpression system: Human cells · Tag-free · Animal-free\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eInterleukin-2 is a glycosylated, short-range cytokine produced mainly by activated T cells. It drives proliferation and survival of activated T cells, can stimulate NK cells and also contributes to the maintenance of regulatory T cells.\u003c\/p\u003e\n\u003cp\u003eIL-2 signals through IL-2 receptor complexes and activates JAK1\/JAK3–STAT5 together with PI3K–AKT and MAPK pathways. Receptor composition and IL-2 concentration strongly shape which cells respond, and outcomes also depend on activation state, culture density, companion cytokines such as IL-7, IL-15 and IL-21, and exposure time.\u003c\/p\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cp\u003eIL-2 supports the expansion and survival of several lymphocyte populations and is a standard ligand for IL-2 receptor signaling studies. The table summarizes typical workflow placement; it is a planning guide, not a universal protocol.\u003c\/p\u003e\n\u003cdiv class=\"bhp-app-wrap\"\u003e\u003ctable class=\"bhp-app-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRole of IL-2\u003c\/th\u003e\n\u003cth\u003eCompanion signals and context\u003c\/th\u003e\n\u003cth\u003eSuggested readouts\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActivated conventional T cells\u003c\/td\u003e\n\u003ctd\u003eProliferation and survival\u003c\/td\u003e\n\u003ctd\u003eTCR\/CD3-CD28 or antigen activation\u003c\/td\u003e\n\u003ctd\u003eExpansion, viability, phenotype, cytokines and cytotoxicity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNK-cell culture\u003c\/td\u003e\n\u003ctd\u003eGrowth and activation support\u003c\/td\u003e\n\u003ctd\u003eIL-15 and\/or IL-21 depending on protocol\u003c\/td\u003e\n\u003ctd\u003eCD56\/CD16 phenotype, degranulation, killing and cytokines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eγδ T-cell culture\u003c\/td\u003e\n\u003ctd\u003eExpansion after phosphoantigen-related activation\u003c\/td\u003e\n\u003ctd\u003eZoledronate\/pamidronate or IPP in protocol-specific systems\u003c\/td\u003e\n\u003ctd\u003eVδ2 frequency, proliferation, cytokines and tumor-cell killing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory T-cell research\u003c\/td\u003e\n\u003ctd\u003eContext-dependent survival and STAT5 support\u003c\/td\u003e\n\u003ctd\u003eDefined TCR stimulation and low-dose experimental design\u003c\/td\u003e\n\u003ctd\u003eFOXP3, CD25, suppressive function and pSTAT5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003ePlanning considerations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDefine the immune-cell stage and confirm that the target population expresses the relevant IL-2 receptor components.\u003c\/li\u003e\n\u003cli\u003eStart from a peer-reviewed or internally qualified concentration, then run a dose response for the cell source, basal medium and readout.\u003c\/li\u003e\n\u003cli\u003eControl timing and companion cytokines, since effects depend on signal order, duration and pathway interactions; include no-factor, vehicle and pathway-response controls.\u003c\/li\u003e\n\u003cli\u003eAssess identity, viability, signaling and function rather than cell number alone. No EC50 or universal working concentration applies without lot- or protocol-specific evidence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eProtein Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eIL-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative names\u003c\/th\u003e\n\u003ctd\u003eInterleukin-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression system\u003c\/th\u003e\n\u003ctd\u003eHuman cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStructure\u003c\/th\u003e\n\u003ctd\u003eGlycosylated monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProtein family\u003c\/th\u003e\n\u003ctd\u003eInterleukin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression region\u003c\/th\u003e\n\u003ctd\u003eFull length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003ctd\u003eTag-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAnimal origin\u003c\/th\u003e\n\u003ctd\u003eAnimal-free \/ xeno-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular weight\u003c\/th\u003e\n\u003ctd\u003eApproximately 15 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eEndotoxin level\u003c\/th\u003e\n\u003ctd\u003e\u0026lt;0.5 EU\/µg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eLyophilized from a 0.2 µm-filtered solution in PBS without carrier protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiological activity\u003c\/th\u003e\n\u003ctd\u003eDose-dependent proliferation of mouse CTLL-2 cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eApplications\u003c\/th\u003e\n\u003ctd\u003eStem Cell Differentiation, Immunotherapy, T Cell Activation Assay, Cell Proliferation, Cytotoxicity Assay, Cell Signaling Studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eBiological Activity \u0026amp; Quality Control\u003c\/h2\u003e\n\u003cp\u003eActivity is determined in a CTLL-2 assay, in which the protein drives proliferation of these mouse cytotoxic T cells in a dose-dependent way.\u003c\/p\u003e\n\u003cp\u003eLot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.\u003c\/p\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eBriefly centrifuge the vial before opening.\u003c\/li\u003e\n\u003cli\u003eReconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.\u003c\/li\u003e\n\u003cli\u003eMix gently and prepare single-use aliquots under sterile conditions.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles; a manual-defrost freezer is recommended.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eStorage \u0026amp; Shipping\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eAs supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003ePlease contact us to confirm shipping conditions for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eSelected References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eMalek TR (2008) The biology of interleukin-2. Annu Rev Immunol 26:453-479. \u003ca href=\"https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090357\" target=\"_blank\" rel=\"noopener\"\u003e10.1146\/annurev.immunol.26.021607.090357\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eBoyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12:180-190. \u003ca href=\"https:\/\/doi.org\/10.1038\/nri3156\" target=\"_blank\" rel=\"noopener\"\u003e10.1038\/nri3156\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eWaldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601. \u003ca href=\"https:\/\/doi.org\/10.1038\/nri1901\" target=\"_blank\" rel=\"noopener\"\u003e10.1038\/nri1901\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\u003cp style=\"margin:0\"\u003eHandle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.\u003c\/p\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cem\u003eFor research use only. Not for diagnostic or therapeutic use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"StemImmune LLC","offers":[{"title":"10 ug","offer_id":67641422217581,"sku":"HCT-I2-0010","price":102.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":67641432572269,"sku":"HCT-I2-0100","price":407.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/IL2-500x500.png?v=1791572833","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-il-2-protein-bhp22200024","provider":"BioHippo","version":"1.0","type":"link"}